Pfizer's academic-partnered R&D unit is scrapped as part of cost-cutting measures

[cafead]

via Pfizer’s cost cuts that began last year have stretched to the closure of a well-known internal R&D team that focused on partnering with physician-scientists to launch new medicines, including one that ultimately became the center of a $7.1 billion acquisition from Roche.

article source